ArticleAmerican journal of respiratory and critical care medicine2023
NRF2 Activation Reprograms Defects in Oxidative Metabolism to Restore Macrophage Function in Chronic Obstructive Pulmonary Disease.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
19.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Exhaled breath volatile organic compounds (VOCs) detection methods: GC-MS versus eNose in COPD diagnosis-a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Insight into Nrf2: a bibliometric and visual analysis from 2000 to 2022.Frontiers in genetics · 2023Pooled it
- Alveolar Macrophages: Development, Respiratory Homeostasis, Signal Pathways, Diseases, and Therapeutic Opportunities.MedComm · 2026Review
- Resveratrol Inhibits Macrophage Glucose Metabolism Reprogramming and Inflammatory Activation to Delay COPD Progression Through the TLR4/HK2 Pathway.Journal of cellular physiology · 2026Article
- Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation.Experimental hematology & oncology · 2026Review
- Smoker's Lungs: Quo Vadis? Exploring the Shared and Individual Smoking-Related Molecular Pathways of Emphysema, Carcinoma, and Fibrosis - An Illustrative Review.Thoracic cancer · 2026Review
- The cell with many faces: lung macrophage plasticity and function in response to environmental and pathogenic insults.Physiological reviews · 2026Review
- Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026Review
- Skeletal Muscle Redox Signaling in Health and Disease: From Molecular Mechanisms to Therapeutic Exercise Strategies.Antioxidants (Basel, Switzerland) · 2026Review
- Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions.BMC medicine · 2026Review
- Construction of chronic inflammation and mitochondrial energy metabolism-associated predictive and therapeutic models for lung adenocarcinoma patients.Discover oncology · 2026Article
- Proteomics-Based Study of Potential Emphysema Biomarkers Reveals Systemic Redox System and Extracellular Matrix Component Dysregulation.Diagnostics (Basel, Switzerland) · 2026Article
- The ErbB-tyrosine kinase inhibitor, neratinib, has anti-inflammatory effects in multimorbidity by increasing macrophage efferocytosis via the upregulation of MerTK.Journal of inflammation (London, England) · 2026Article
- Immune-adaptive pathogen variation reveals targetable mediators of gram-positive bacterial killing in macrophages.Science advances · 2026Article
- Beyond a metabolite: lactate and lactylation in lung diseases.Respiratory research · 2026Review
- Targeting PLA2G7 ameliorates high-fat diet-induced pulmonary injury in obese mice, uncovering a key mechanistic link to obesity-associated COPD.Respiratory research · 2026Article
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
- Nuclear Factor Erythroid 2-Related Factor 2 in Chronic Obstructive Pulmonary Disease Progression: Regulation of Macrophage Polarization and Hyaluronic Acid Metabolism.International journal of chronic obstructive pulmonary disease · 2026Article
- Breaking barriers in pulmonary health of patients with metabolic diseases: senolytics and beyond.Frontiers in aging · 2026Review
- COPD-OSA overlap syndrome: inflammatory and oxidative stress mechanisms, biomarkers, and clinical implications.Frontiers in medicine · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 10 institutions in 4 countries.
Eilise M RyanUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Pranvera SadikuUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Patricia CoelhoUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Emily R WattsUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Ailiang ZhangUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Andrew J M HowdenDivision of Cell Signalling and Immunology, University of Dundee, Dundee, United Kingdom.
Manuel A Sanchez-GarciaUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Martin BewleyDepartment of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Joby ColeDepartment of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom.
Brian J McHughUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Wesley VermaelenMetabolomics Expertise Centre, VIB-KU Leuven Centre for Cancer Biology, Leuven, Belgium.
Bart GhesquiereMetabolomics Expertise Centre, VIB-KU Leuven Centre for Cancer Biology, Leuven, Belgium.
Peter CarmelietLaboratory of Angiogenesis and Vascular Metabolism, Centre for Cancer Biology, VIB, Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.
Giovanny Rodriguez BlancoCancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, and.
Alex Von KriegsheimCancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, and.
Yolanda SanchezGlaxoSmithKline Research & Development, Collegeville, Pennsylvania.
William RumseyGlaxoSmithKline Research & Development, Collegeville, Pennsylvania.
James F CallahanGlaxoSmithKline Research & Development, Collegeville, Pennsylvania.
George CooperUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Nicholas ParkinsonMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.
Kenneth BaillieMRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-5258-793X
Doreen A CantrellDivision of Cell Signalling and Immunology, University of Dundee, Dundee, United Kingdom.
John McCaffertyNHS Lothian, Respiratory Medicine, Edinburgh, United Kingdom; and.
Gourab ChoudhuryNHS Lothian, Respiratory Medicine, Edinburgh, United Kingdom; and.
Dave SinghDivision of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester, United Kingdom.
David H DockrellUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Moira K B WhyteUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Sarah R WalmsleyUniversity of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute.
Centre for Inflammation Research · GBGlaxoSmithKline (United States) · USEdinburgh Cancer Research · GBInstitute of Genetics and Cancer · GBNHS Lothian · GBUniversity of Dundee · GBUniversity of Sheffield · GBVIB-KU Leuven Center for Cancer Biology · BESun Yat-sen University · CNUniversity of Manchester · GB
Funding
Medical Research Council MR/N02995X/1Wellcome Trust 098516Wellcome Trust 203644Wellcome Trust 205023/Z/16/ZWellcome Trust 209220Wellcome Trust 209220/Z/17/ZWellcome Trust R43999
Abstract
PubMed holds no abstract for this paper.
Indexed as
NF-E2-Related Factor 2Pulmonary Disease, Chronic ObstructiveHumansMacrophagesMalate DehydrogenaseOxidative StressMalate Dehydrogenasemalate dehydrogenase (decarboxylating)NF-E2-Related Factor 2COPDmacrophagemalic enzyme 1metabolismnuclear factor erythroid 2–related factor 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.